For example, various preclinical studies have shown that treatment with bevacizumab (anti-VEGF antibody) or DC-101 (anti-mouse VEGFR-2 antibody) showed strong efficacy in many xenograft models by suppression of tumor angiogenesis.6,22. The gene discussed is KDR; the disease is neoplasm.